Drugs / Donor bone marrow cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01889381 | Aug 2012 → Aug 2026 overdue | craniofacial and skeletal defects | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor bone marrow cells | “Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host...” NCT01889381 ↗ |
| Modality | Cell therapy | “novel bone marrow cell-based therapy” NCT01889381 ↗ |